Frequency Changes in HLA-I Alleles: A Marker to Guide Immunotherapy in Lung Adenocarcinoma Patients and Its Relationship with Tumor Mutational Burden and PD-L1 Expression

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2023 May 29

PMID 37246469

Authors

Xuanpeng Wu

Hao Wang

Fei Xue

Tao Jiang

Nanzheng Chen

Tianju Wang

Yong Zhang

Guangjian Zhang

Junke Fu

Qifei Wu

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the study was to investigate differences in HLA-I alleles between lung adenocarcinoma patients and healthy controls and determine their association with PD-L1 expression and tumor mutational burden (TMB) to understand the mechanism underlying lung adenocarcinoma susceptibility.

Methods: Differences in HLA allele frequencies between the two groups were analyzed in a case-control study. PD-L1 expression and TMB in lung adenocarcinoma patients were determined and their relationships with HLA-I were analyzed.

Results: The lung adenocarcinoma group showed significantly higher HLA-A*30:01 (p = 0.0067, odds ratio [OR], 1.834; 95% confidence interval [CI]: 1.176-2.860), B*13:02 (p = 0.0050, OR, 1.855; 95% CI: 1.217-2.829), and C*06:02 (p = 0.0260, OR, 1.478; 95% CI: 1.060-2.060) and significantly lower B*51:01 (p = 0.0290, OR, 0.6019; 95% CI: 0.3827-0.9467), and C*14:02 (p = 0.0255, OR, 0.5089; 95% CI: 0.2781-0.9312) than the control group. Haplotype analysis results showed that HLA-A*30:01-B*13:02 (p = 0.0100, OR, 1.909; 95% CI: 1.182-3.085), A*11:01-C*01:02 (p = 0.0056, OR, 1.909; 95% CI: 1.182-3.085), A*30:01-C*06:02 (p = 0.0111, OR, 1.846; 95% CI: 1.147-2.969), and B*13:02-C*06:02 (p = 0.0067, OR, 1.846; 95% CI: 1.147-2.969) frequencies significantly increased and B*51:01-C*14:02 (p = 0.0219, OR, 0.490; 95% CI: 0.263-0.914) frequency significantly decreased in lung adenocarcinoma patients. Three-locus haplotype analysis showed that HLA-A*30:01-B*13:02-C*06:02 frequency (p = 0.0100, OR, 1.909; 95% CI: 1.182-3.085) significantly increased in patients.

Conclusion: HLA-A*30:01, B*13:02, and C*06:02 may be the susceptibility genes and HLA-B*51:01 and C*14:01 act as the resistance genes of lung adenocarcinoma. The changes in HLA-I allele frequencies had no association with PD-L1 expression and TMB among these patients.

Citing Articles

Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression.

Wu X, Wang H, Xue F, Jiang T, Chen N, Wang T Thorac Cancer. 2023; 14(20):1932-1940.

PMID: 37246469 PMC: 10344735. DOI: 10.1111/1759-7714.14939.

References

Shin D, Ribas A . The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr Opin Immunol. 2015; 33:23-35. DOI: 10.1016/j.coi.2015.01.006. View

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

Sun C, Mezzadra R, Schumacher T . Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018; 48(3):434-452. PMC: 7116507. DOI: 10.1016/j.immuni.2018.03.014. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Zhao M, Qiu L, Tao N, Zhang L, She Q, Zeng F . HLA DRB allele polymorphisms and risk of cervical cancer associated with human papillomavirus infection: a population study in China. Eur J Gynaecol Oncol. 2013; 34(1):54-9. View

Abed A, Calapre L, Lo J, Correia S, Bowyer S, Chopra A . Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. J Immunother Cancer. 2020; 8(2). PMC: 7684824. DOI: 10.1136/jitc-2020-001620. View

Negrao M, Lam V, Reuben A, Rubin M, Landry L, Roarty E . PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019; 14(6):1021-1031. DOI: 10.1016/j.jtho.2019.02.008. View

Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O . OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014; 30(23):3310-6. PMC: 4441069. DOI: 10.1093/bioinformatics/btu548. View

10.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

11.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

12.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

13.

Hudson K, Cross N, Jordan-Mahy N, Leyland R . The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020; 11:568931. PMC: 7609400. DOI: 10.3389/fimmu.2020.568931. View

14.

Yang L, Wang L, Shi G, Ni L, Song C, Zhang Z . Analysis of HLA-A, HLA-B and HLA-DRB1 alleles in Chinese patients with lung cancer. Genet Mol Res. 2010; 9(2):750-5. DOI: 10.4238/vol9-2gmr735. View

15.

Ready N, Hellmann M, Awad M, Otterson G, Gutierrez M, Gainor J . First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol. 2019; 37(12):992-1000. PMC: 6494267. DOI: 10.1200/JCO.18.01042. View

16.

Wu X, Wang H, Xue F, Jiang T, Chen N, Wang T . Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression. Thorac Cancer. 2023; 14(20):1932-1940. PMC: 10344735. DOI: 10.1111/1759-7714.14939. View

17.

Shukla S, Rooney M, Rajasagi M, Tiao G, Dixon P, Lawrence M . Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015; 33(11):1152-8. PMC: 4747795. DOI: 10.1038/nbt.3344. View

18.

Ng M, Cheng S, Lai P, Ling K, Lau K, Cheng C . Association of polymorphism of human leukocyte antigen alleles with development of hepatocellular carcinoma in Hong Kong Chinese. Hong Kong Med J. 2012; 18 Suppl 6:37-40. View

19.

Chowell D, Krishna C, Pierini F, Makarov V, Rizvi N, Kuo F . Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019; 25(11):1715-1720. PMC: 7938381. DOI: 10.1038/s41591-019-0639-4. View

20.

Overman M, Lonardi S, Wong K, Lenz H, Gelsomino F, Aglietta M . Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018; 36(8):773-779. DOI: 10.1200/JCO.2017.76.9901. View